DECISION-CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients withChronIc Total OccluSION : A randomized, multi-center trial to evaluate the long term efficacy of drug-eluting stent implantation compared with optimal medical treatment in patients with chronic total occlusion - DECISION-CTO

Prof SeungJung Park0 个研究点目标入组 88 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with angina or silent ischemia and documented ischemia
•2.Patients who are eligible for intracoronary stenting
•3.Age > 18 years
•Angiographic
•1.De novo lesion CTO
•2.Reference vessel size 2.5 mm by visual estimation
•3.At least one CTO lesions located in proximal or mid epicardial coronary artery. (If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery)
•CTO definition: TIMI flow 0 and estimated duration over 3 months The duration of the occlusion was determined by the interval from the last episode of acute coronary syndrome, or In patients without a history of acute coronary syndrome, from the first episode of effort angina consistent with the location of the occlusion
•1.Angiographically defined total occlusion over 3 months
•2.If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)

•1.History of bleeding diathesis or coagulopathy
•2.Pregnant state
•3.Three vessel CTO
•4.Known hypersensitivity or contra-indication to contrast agent and heparin
•5.ST-elevation acute myocardial infarction requiring primary stenting
•6.Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels 4) Distal epicardial coronary artery CTO lesions
•7.Hematological disease
•8.Hepatic dysfunction, liver enzyme (ALT and AST) elevation 3 times normal
•9.Renal dysfunction, creatinine more than 2.0
•10.Contraindication to aspirin, clopidogrel or other commercial antiplatelet agent
•11.Left ventricular ejection fraction
•12.Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
•13.Non-cardiac co-morbid conditions are present with limited life expectancy or that may result in protocol non-compliance (per site investigators medical judgment).

发起方

Prof SeungJung Park